<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161299">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720095</url>
  </required_header>
  <id_info>
    <org_study_id>CDHA_RS/2010-116</org_study_id>
    <nct_id>NCT01720095</nct_id>
    <nct_alias>NCT01041053</nct_alias>
  </id_info>
  <brief_title>Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis</brief_title>
  <official_title>A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (NIASPAN) as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital District Health Authority, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital District Health Authority, Canada</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to
      antipsychotic medications will it help maintain or improve  cognitve functioning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>standardized and experimental measures of attention, memory, and executive function. Measurement tools=MATRICS; DalCAB</measure>
    <time_frame>change in cognitive function from baseline to 3, 6, and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcomes will be measured by comparison of pre-treatment, post-treatment and twelve month</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Psychosis</condition>
  <arm_group>
    <arm_group_label>Niaspan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>these are the first episode psychosis patients that are randomized to receive niaspan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>this is the group of healthy controls for cognitive outcome measures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>first episode control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>first episode psychosis patients who are randomized to no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niaspan</intervention_name>
    <arm_group_label>Niaspan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ALL SUBJECTS

          1. Must understand the nature of the study, must provide written informed consent prior
             to the conduct of any study procedures/assessments and are willing/able to
             participate in study procedures/assessments as specified in this protocol.

          2. Must be between the ages of 18 - 35

        PATIENTS

          1. Within one year of initial DSM 1V TR diagnosis of schizophreniform psychosis,
             schizophrenia, schizoaffective disorder or psychotic disorder NOS

          2. Outpatients

          3. Females of child bearing potential who have a negative serum pregnancy test prior to
             enrolment and agree to use a reliable method of birth control (use of oral
             contraceptives or Norplant; contraceptive injections; contraceptive patch; double
             barrier method; intrauterine devices; partner with vasectomy or abstinence) during
             the study and for one month following the last dose of study drug.

        HEALTHY CONTROLS

        1. Age-matched to experimental groups

        Exclusion Criteria:

          1. Due to their underlying mental disorder are considered by the investigator(s) to be
             unable to provide informed consent and/or unwilling or unable to participate in study
             procedures/assessments

          2. Are judged by the investigator(s) (based on history, mental status examination or
             clinical impression) as being at significant risk of self-injurious/suicidal or
             violent/homicidal behaviour

          3. Meet criteria for substance abuse or dependence (excluding nicotine and caffeine) as
             defined by DSM IV-TR at the time of screening and/or within the preceding 6 months

          4. Have unstable medical, psychiatric, neurological or behavioural disorders that may
             interfere in the conduct or interpretation of the study.

          5. Have a history of pre-existing liver dysfunction and/or at screening have abnormal
             liver function tests (ALT&gt;2x upper limit of normal; AST&gt;3x upper limit of normal;
             Bilirubin&gt;1.5x upper limit of normal)

          6. Have a past or current history of  peptic ulcer, gout or bleeding problems

          7. Have a past or current history of hypophosphatemia

          8. Have a history of head injury resulting in loss of consciousness of &gt; 5 minutes or
             other neurological disorder (e.g., seizures, stroke, MS)

          9. Are currently taking a vitamin or nutritional supplement containing a dose of
             niacin/nicotinic acid above 100 mg/day.

         10. Are currently receiving treatment with any of  the following medications:

               1. Anticoagulants

               2. Statins

               3. Antihypertensives

         11. Are currently receiving treatment for Type 1 or Type 2 diabetes

         12. Have a history of allergic reactions to NIASPAN or any of its non-medicinal
             ingredients (methylcellulose, povidone, stearic acid), niacin or nicotinic acid

         13. Are currently participating in any other investigational drug study

         14. Are a professional or staff member affiliated with the Nova Scotia Early Psychosis
             Program or are an immediate family member defined as spouse, parent, child, sibling,
             grandparent or grandchild
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather I Milliken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital District Health Authority, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather I Milliken, MD</last_name>
    <phone>902-473-2976</phone>
  </overall_contact>
  <location>
    <facility>
      <name>NS Early Psychosis Program</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather I Milliken, MD</last_name>
      <phone>902-473-2976</phone>
    </contact>
    <investigator>
      <last_name>Heather I Milliken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NS Early Psychosis Program</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather I Milliken, MD</last_name>
      <phone>902-473-2976</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 31, 2012</lastchanged_date>
  <firstreceived_date>October 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
